Fontoura et al., 2010 - Google Patents
Multiple sclerosis therapies: molecular mechanisms and futureFontoura et al., 2010
View PDF- Document ID
- 14792695051802931556
- Author
- Fontoura P
- Garren H
- Publication year
- Publication venue
- Molecular Basis of Multiple Sclerosis: The Immune System
External Links
Snippet
The current treatments for multiple sclerosis (MS) are, by many measures, not satisfactory. The original interferon-β therapies were not necessarily based on an extensive knowledge of the pathophysiological mechanisms of the disease. As more and more insight has been …
- 201000006417 multiple sclerosis 0 title abstract description 168
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gholamzad et al. | A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future | |
| Rommer et al. | Immunological aspects of approved MS therapeutics | |
| Milo | Therapies for multiple sclerosis targeting B cells | |
| Lopez-Diego et al. | Novel therapeutic strategies for multiple sclerosis—a multifaceted adversary | |
| Hohlfeld | Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. | |
| Buck et al. | Treatment of multiple sclerosis: current concepts and future perspectives | |
| Noseworthy et al. | Treatment of multiple sclerosis: recent trials and future perspectives | |
| Menge et al. | Disease-modifying agents for multiple sclerosis: recent advances and future prospects | |
| Wiend et al. | Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials | |
| Barun et al. | Treatment of multiple sclerosis with anti-CD20 antibodies | |
| Rommer et al. | Requirement for safety monitoring for approved multiple sclerosis therapies: an overview | |
| Hemmer et al. | Toward the development of rational therapies in multiple sclerosis: what is on the horizon? | |
| US20090196850A1 (en) | Anti-Kir Combination Treatments and Methods | |
| JP2008506778A (en) | FLT3 inhibitors for immunosuppression | |
| UA124269C2 (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| Bittner et al. | Neuroimmunotherapies targeting T cells: from pathophysiology to therapeutic applications | |
| Manjunatha et al. | Multiple sclerosis: therapeutic strategies on the horizon | |
| Fontoura et al. | Multiple sclerosis therapies: molecular mechanisms and future | |
| US20240350489A1 (en) | Lou064 for treating multiple sclerosis | |
| TW202104219A (en) | Solid forms of a toll-like receptor modulator | |
| Karussis | Immunotherapy of multiple sclerosis: the state of the art | |
| Buc | New biological agents in the treatment of multiple sclerosis. | |
| Greenberg et al. | Future research directions in multiple sclerosis therapies | |
| Konitsioti et al. | Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review | |
| Bellanca et al. | Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability? |